EUCTR2013-000952-17-CZ进行中(未招募)不适用
The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder. - D-KET-mTOR
Prague Psychiatric Centre0 个研究点开始时间: 2013年3月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women at the age between 18 to 65 years, with dextromanual dominance, t.j. scores 100 in Edinburgh Handedness Inventory (EHI).
- •2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic symptoms, on the clinical investigation basis, by Mini international neuropsychiatry interview (M.I.N.I., Czech version 5.0.0.) - structured interview for psychiatric disorders on axis I based on DSM- IV.
- •3. Input score in MADRS (Montgomery-Asberg Depression Rating Scale) higher than 20, what matches medium severity of clinical state in CGI (ClinicalGlobal Impression ) scale higher or equal with 4.
- •4. Mental ability understand and sign informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Increased vulnerability to the development of psychosis ascertained on the basis a) M.I.N.I., b) family anamnesis of psychosis at relatives I. and II. degree.
- •2. Presence of another psychiatric disorder on axis I base on DSM- IV less than 6 months before inclusion to the study.
- •3. Contraindication for ketamine administration (hypertension, heart defect, severe cardiovascular disease, cerebrovascular accident in anamnesis, intracranial hypertension, glaucoma, hyperthyreosis, convulsions in anamnesis).
- •4. Using of drugs with strong anticholinergic efect.
- •5. Pregnant women, breastfeeding women or women without appropriate contraception.
- •6. Electroconvulsive treatment in the last 2 months before visit 1.
- •7. Treatment augmentation by lamotrigine, lithium, clozapine or IMAO (inhibitor of monoaminooxidase) in the last 2 weeks before visit 1.
- •8. Pharmaceuticals, illness and states, which may have influence on EEG (benzodiazepines, classical antipsychotics, head injury, encephalitis, epilepsy, etc.).
- •9. Clinically assessed serious suicidal risk.
研究者
相似试验
已完成
2 期
Evaluation of the molecular effects of metformin and improvement of symptoms in osteoarthritis patientsOsteoarthritis.Osteoarthritis of kneeIRCT20150202020908N2Shiraz University of Medical Sciences100
进行中(未招募)
1 期
Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study.CTIS2023-508093-28-00Odense University Hospital136
撤回
1 期
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDSAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Sars-CoV2Respiratory FailureNCT04482712The University of Texas Health Science Center at San Antonio
招募中
不适用
mTOR as Mediator of Insulin Sensitivity StudyInsulin SensitivityNCT05233722University of Copenhagen10
终止
2 期
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaSquamous Cell CarcinomaNCT01009203New Mexico Cancer Care Alliance13
